Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033
Global NGS Market: Industry Overview
The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033. The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, the growing prevalence of non-communicable disorders, and the advancement in the performance of NGS platforms.
Market Lifecycle Stage
The global NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing. The opportunity for growth of the global NGS market lies in the development of economical and portable technologies.
Impact of COVID-19
NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19 and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.
However, while NGS testing shot up in the research laboratories studying the transmission of the SARS-CoV-2 virus, NGS testing in the clinical setting witnessed a significant drop. The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, or Rest-of-the-World.
Market Segmentation:
Segmentation 1: by Offering
Segmentation 2: by Company
Segmentation 3: by Throughput
Segmentation 4: by Technology Type
Segmentation 5: by Sequencing
Segmentation 6: by Application
Segmentation 7: by End User
Segmentation 8: by Country
Recent Developments in the Global NGS Market
The following are the drivers for the global NGS market:
Type: The global NGS market has been extensively segmented on the basis of various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market.
Competitive Strategy: The global NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the global NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.
Key Companies Profiled
The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033. The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, the growing prevalence of non-communicable disorders, and the advancement in the performance of NGS platforms.
Market Lifecycle Stage
The global NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing. The opportunity for growth of the global NGS market lies in the development of economical and portable technologies.
Impact of COVID-19
NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19 and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.
However, while NGS testing shot up in the research laboratories studying the transmission of the SARS-CoV-2 virus, NGS testing in the clinical setting witnessed a significant drop. The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, or Rest-of-the-World.
Market Segmentation:
Segmentation 1: by Offering
- Consumables
- Library Preparation Kits
- Sequencing Kits
- Equipment
- Services
Segmentation 2: by Company
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific BioSciences of California, Inc.
- Oxford Nanopore Technologies plc.
- Other Companies
Segmentation 3: by Throughput
- High- and Ultra-High-Throughput
- Medium-Throughput
- Low-Throughput
Segmentation 4: by Technology Type
- Sequencing by Synthesis
- In Torrent Semiconductor Sequencing
- Single Molecule Real-Time Sequencing
- Nanopore Sequencing Technology
- Other Technologies
Segmentation 5: by Sequencing
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing
Segmentation 6: by Application
- Clinical Diagnostics
- Oncology
- Non-Oncology
- Research
- Oncology
- Non-Oncology
Segmentation 7: by End User
- Academic and Research Institutes
- Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
- Other End Users
Segmentation 8: by Country
- North America - U.S., Canada
- Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, New Zealand, and Rest-of-Asia-Pacific
- Middle East - U.A.E., K.S.A., Israel, Rest-of-Middle East
- Rest-of-the-World - Latin America, Rest-of-Rest-of-the-World
Recent Developments in the Global NGS Market
- In April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.’s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.
- In March 2023, Sophia Genetics partnered with Agilent Technologies Inc. to integrate its Sophia DDM Platform with Agilent Technologies Inc.’s research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay kit.
- In March 2023, Thermo Fisher Scientific Inc. collaborated with Pfizer to expand access to NGS-based lung and breast cancer testing in more than 30 countries.
- In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing.
- In October 2022, Pacific Biosciences of California, Inc. introduced two new sequencing systems, namely, Revio and Onso.
- In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.
The following are the drivers for the global NGS market:
- Decreasing Cost of Genome Sequencing
- Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
- Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
- Advantages of NGS Technology Over Other Technologies
- Concerns Surrounding Privacy of Patient Genomic Data
- Lack of Complete Reimbursement Coverage for NGS Testing
Type: The global NGS market has been extensively segmented on the basis of various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market.
Competitive Strategy: The global NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the global NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.
Key Companies Profiled
- BGI Group
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Pillar Biosciences
- Burning Rock Biotech Limited
- Singular Genomics Systems, Inc.
- DANAHER CORPORATION
- F. Hoffmann-La Roche Ltd
- Twist Bioscience Corporation
- Revvity, Inc.
- Centogene N.V.
- Element Biosciences
- Ultima Genomics
- Genes2me
- LifeStrands Genomics Pte. Ltd.
- Alithea Genomics
- Real Seq Biosciences
1 MARKETS
1.1 Product Definition
1.1.1 Inclusion and Exclusion Criteria
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Next-Generation IVD Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 Introduction
2.1.1 Global Next-Generation IVD Market Outlook
2.1.1.1 POC-IVD
2.1.1.2 Global Diagnostic Expenditures
2.1.1.3 Pricing Patterns of Next-Generation IVD
2.1.2 Market Size and Growth Potential
2.1.2.1 Short-Term Impact (2020-2025)
2.1.2.2 Long-Term Impact (2026-2033)
2.1.3 Product Benchmarking by Next- Generation In-vitro Diagnostics Market, (by Type)
2.2 COVID-19 Impact on the Next-Generation IVD Market
2.2.1 Impact on Operations
2.2.2 COVID-19 Impact: Current Scenario of the Market
2.2.3 Pre-COVID Assessment
2.2.4 Post-COVID-19 Market Assessment
3 INDUSTRY ANALYSIS
3.1 Legal Requirements
3.1.1 Legal Requirements and Framework in the U.S.
3.1.2 Legal Requirements and Framework in Europe
3.1.3 Legal Requirements and Framework in Asia-Pacific
3.1.4 Legal Requirement and Framework in Latin America
4 MARKET DYNAMICS
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Technological Advancements in Next-Generation In-Vitro Diagnostics Transforming Healthcare System
4.3.2 Rising Demand of POC Testing Boosting Next-Generation IVD Market
4.3.3 Growing Incidence of Chronic and Acute Diseases Demanding for Early Treatment
4.3.4 Boost in the Next-Generation IVD Market during COVID-19 Pandemic
4.4 Market Challenges
4.4.1 Regulatory Hurdles Related to Next-Generation IVD Technologies
4.4.2 Poor Reimbursement Scenario
4.5 Market Opportunities
4.5.1 Rising Number of Next-Generation IVD Companies Involved in Business Expansion
4.5.2 Inclination of Emerging Companies toward Next-Generation IVD
5 COMPETITIVE LANDSCAPE
5.1 Overview
5.2 Corporate Strategies
5.2.1 Acquisitions
5.2.2 Synergistic Activities
5.3 Business Strategies
5.3.1 Product Launches and Approvals
5.3.2 Business Expansions, Fundings, and Other Activities
5.4 Market Share Analysis
5.4.1 Market Share Analysis (by Company)
5.5 Growth Share Analysis
5.5.1 Growth Share Analysis (by Product)
6 GLOBAL NEXT-GENERATION IVD MARKET (BY PRODUCT), ($BILLION), 2022-2033
6.1 Overview
6.2 Consumables
6.3 Instruments
6.4 Software
7 GLOBAL NEXT-GENERATION IVD MARKET (BY TYPE), ($BILLION), 2022-2033
7.1 Overview
7.2 Core Laboratory Diagnostics
7.2.1 Test Volume
7.2.2 Market Size and Forecast
7.2.2.1 Immunoassay
7.2.2.2 Hematology
7.2.2.3 Clinical Chemistry
7.2.2.4 Other Core Laboratory Diagnostics
7.3 POC Testing
7.3.1 Test Volume
7.3.2 Market Size and Forecast
7.4 Molecular Diagnostics
7.4.1 Test Volume
7.4.2 Market Size and Forecast
7.4.2.1 PCR
7.4.2.2 NGS
7.4.2.3 INAAT
7.4.2.4 Microarray
7.4.2.5 ISH
7.4.2.6 Immunohistochemistry
7.4.2.7 Other Molecular Diagnostics
8 GLOBAL NEXT-GENERATION IVD MARKETS (BY APPLICATION), $BILLION, 2022-2033
8.1 Overview
8.2 Diabetes
8.2.1 Type
8.2.2 Type
8.3 Infectious Diseases
8.3.1 Tuberculosis
8.3.2 Malaria
8.3.3 Hepatitis
8.3.4 Other Infectious Diseases
8.4 Oncology/Cancer
8.4.1 Solid Tumor
8.4.2 Hematological Malignancies
8.5 Cardiology
8.5.1 Cardiac Ischemia
8.5.2 Coronary Artery Diseases
8.6 Other Applications
9 GLOBAL NEXT-GENERATION IVD MARKET (BY END USER), ($BILLION), 2022-2033
9.1 Overview
9.1.1 Hospitals and Clinics
9.1.2 Diagnostic Laboratories
9.1.3 Academic and Research Institutions
9.1.4 Other End Users
10 GLOBAL NEXT-GENERATION IVD MARKET, BY REGION, $MILLION, 2022-2033
10.1 Overview
10.2 North America
10.2.1 Market Dynamics
10.2.2 Market Size and Forecast
10.2.2.1 North America Next-Generation IVD Market (by End User)
10.2.2.2 North America Next-Generation IVD Market (by Type)
10.2.2.2.1 North America Next-Generation Core Laboratory IVD Market, (by Type)
10.2.2.3 North America Next-Generation IVD Market (by Country)
10.2.2.3.1 U.S.
10.2.2.3.1.1 Market Size and Forecast
10.2.2.3.1.1.1 U.S. Next-Generation IVD Market (by End User)
10.2.2.3.1.1.2 U.S. Next-Generation IVD Market (by Type)
10.2.2.3.2 Canada
10.2.2.3.2.1 Market Size and Forecast
10.2.2.3.2.1.1 Canada Next-Generation IVD Market (by End User)
10.2.2.3.2.1.2 Canada Next-Generation IVD Market (by Type)
10.3 Europe
10.3.1 Market Dynamics
10.3.2 Market Size and Forecast
10.3.2.1 Europe Next-Generation IVD Market (by End User)
10.3.2.2 Europe Next-Generation IVD Market (by Type)
10.3.2.2.1 Europe Next-Generation Core Laboratory IVD Market, (by Type)
10.3.2.3 Europe Next-Generation IVD Market (by Country)
10.3.2.3.1 Germany
10.3.2.3.1.1 Market Size and Forecast
10.3.2.3.1.1.1 Germany Next-Generation IVD Market (by End User)
10.3.2.3.1.1.2 Germany Next-Generation IVD Market (by Type)
10.3.2.3.2 France
10.3.2.3.2.1 Market Size and Forecast
10.3.2.3.2.1.1 France Next-Generation IVD Market (by End User)
10.3.2.3.2.1.2 France Next-Generation IVD Market (by Type)
10.3.2.3.3 U.K.
10.3.2.3.3.1 Market Size and Forecast
10.3.2.3.3.1.1 U.K. Next-Generation IVD Market (by End User)
10.3.2.3.3.1.2 U.K. Next-Generation IVD Market (by Type)
10.3.2.3.4 Italy
10.3.2.3.4.1 Market Size and Forecast
10.3.2.3.4.1.1 Italy Next-Generation IVD Market (by End User)
10.3.2.3.4.1.2 Italy Next-Generation IVD Market (by Type)
10.3.2.3.5 Spain
10.3.2.3.5.1 Market Size and Forecast
10.3.2.3.5.1.1 Spain Next-Generation IVD Market (by End User)
10.3.2.3.5.1.2 Spain Next-Generation IVD Market (by Type)
10.3.2.3.6 Rest-of-Europe
10.3.2.3.6.1 Market Size and Forecast
10.3.2.3.6.1.1 Rest-of-Europe Next-Generation IVD Market (by End User)
10.3.2.3.6.1.2 Rest-of-Europe Next-Generation IVD Market (by Type)
10.4 Asia-Pacific
10.4.1 Market Dynamics
10.4.2 Market Size and Forecast
10.4.2.1 Asia-Pacific Next-Generation IVD Market (by End User)
10.4.2.2 Asia-Pacific Next-Generation IVD Market (by Type)
10.4.2.2.1 Asia-Pacific Next-Generation Core Laboratory IVD Market, (by Type)
10.4.2.3 Asia-Pacific Next-Generation IVD Market (by Country)
10.4.2.3.1 China
10.4.2.3.1.1 Market Size and Forecast
10.4.2.3.1.1.1 China Next-Generation IVD Market (by End User)
10.4.2.3.1.1.2 China Next-Generation IVD Market (by Type)
10.4.2.3.2 Japan
10.4.2.3.2.1 Market Size and Forecast
10.4.2.3.2.1.1 Japan Next-Generation IVD Market (by End User)
10.4.2.3.2.1.2 Japan Next-Generation IVD Market (by Type)
10.4.2.3.3 India
10.4.2.3.3.1 Market Size and Forecast
10.4.2.3.3.1.1 India Next-Generation IVD Market (by End User)
10.4.2.3.3.1.2 India Next-Generation IVD Market (by Type)
10.4.2.3.4 Australia
10.4.2.3.4.1 Market Size and Forecast
10.4.2.3.4.1.1 Australia Next-Generation IVD Market (by End User)
10.4.2.3.4.1.2 Australia Next-Generation IVD Market (by Type)
10.4.2.3.5 South Korea
10.4.2.3.5.1 Market Size and Forecast
10.4.2.3.5.1.1 South Korea Next-Generation IVD Market (by End User)
10.4.2.3.5.1.2 South Korea Next-Generation IVD Market (by Type)
10.4.2.3.6 Rest-of-Asia-Pacific
10.4.2.3.6.1 Market Size and Forecast
10.4.2.3.6.1.1 Rest-of-Asia-Pacific Next-Generation IVD Market (by End User)
10.4.2.3.6.1.2 Rest-of-Asia-Pacific Next-Generation IVD Market (by Type)
10.5 Latin America
10.5.1 Market Dynamics
10.5.2 Market Size and Forecast
10.5.2.1 Latin America Next-Generation IVD Market (by End User)
10.5.2.2 Latin America Next-Generation IVD Market (by Type)
10.5.2.2.1 Latin America Next-Generation Core Laboratory IVD Market, (by Type)
10.5.2.3 Latin America Next-Generation IVD Market (by Country)
10.5.2.3.1 Brazil
10.5.2.3.1.1 Market Size and Forecast
10.5.2.3.1.1.1 Brazil Next-Generation IVD Market (by End User)
10.5.2.3.1.1.2 Brazil Next-Generation IVD Market (by Type)
10.5.2.3.2 Mexico
10.5.2.3.2.1 Market Size and Forecast
10.5.2.3.2.1.1 Mexico Next-Generation IVD Market (by End User)
10.5.2.3.2.1.2 Mexico Next-Generation IVD Market (by Type)
10.5.2.3.3 Rest-of-Latin America
10.5.2.3.3.1 Market Size and Forecast
10.5.2.3.3.1.1 Rest-of-Latin America Next-Generation IVD Market (by End User)
10.5.2.3.3.1.2 Rest-of-Latin America Next-Generation IVD Market (by Type)
10.6 Middle East and Africa
10.6.1 Market Dynamics
10.6.2 Market Size and Forecast
10.6.2.1 Middle East and Africa Next-Generation IVD Market (by End User)
10.6.2.2 Middle East and Africa Next-Generation IVD Market (by Type)
10.6.2.2.1 Middle East and Africa Next-Generation Core Laboratory IVD Market, (by Type)
11 COMPANY PROFILES
11.1 Overview
11.2 Global Next-Generation IVD Market Ecosystem Active Players
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Role of Abbott Laboratories in the Global Next-Generation IVD Market
11.3.3 Financials
11.3.4 Recent Developments
11.3.4.1 Business Strategies
11.3.5 Analyst Perspective
11.4 Agilent Technologies, Inc.
11.4.1 Company Overview
11.4.2 Role of Agilent Technologies, Inc. in the Global Next-Generation IVD Market
11.4.3 Financials
11.4.4 Recent Developments
11.4.4.1 Corporate Strategies
11.4.4.2 Business Strategies
11.4.5 Analyst Perspective
11.5 Becton, Dickinson and Company
11.5.1 Company Overview
11.5.2 Role of Becton, Dickinson and Company in the Global Next-Generation IVD Market
11.5.3 Financials
11.5.4 Recent Developments
11.5.4.1 Corporate Strategies
11.5.4.2 Business Strategies
11.5.5 Analyst Perspective
11.6 bioMйrieux SA (BioFire Diagnostics)
11.6.1 Company Overview
11.6.2 Role of bioMйrieux SA (BioFire Diagnostics) in the Global Next-Generation IVD Market
11.6.3 Financials
11.6.4 Recent Developments
11.6.4.1 Corporate Strategies
11.6.4.2 Business Strategies
11.6.5 Analyst Perspective
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Company Overview
11.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation IVD Market
11.7.3 Financials
11.7.4 Recent Developments
11.7.4.1 Business Strategies
11.7.5 Analyst Perspective
11.8 Danaher Corporation
11.8.1 Company Overview
11.8.2 Role of Danaher Corporation in the Global Next-Generation IVD Market
11.8.3 Financials
11.8.4 Recent Developments
11.8.4.1 Corporate Strategies
11.8.4.2 Business Strategies
11.8.5 Analyst Perspective
11.9 F. Hoffmann-La Roche Ltd. (Roche Molecular Systems, Inc.)
11.9.1 Company Overview
11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation IVD Market
11.9.3 Financials
11.9.4 Recent Developments
11.9.4.1 Business Strategies
11.9.5 Analyst Perspective
11.1 Guardant Health
11.10.1 Company Overview
11.10.2 Role of Guardant Health in the Global Next-Generation IVD Market
11.10.3 Financials
11.10.4 Analyst Perspective
11.11 Illumina, Inc.
11.11.1 Company Overview
11.11.2 Role of Illumina, Inc. in the Global Next-Generation IVD Market
11.11.3 Financials
11.11.4 Recent Developments
11.11.4.1 Corporate Strategies
11.11.4.2 Business Strategies
11.11.5 Analyst Perspective
11.12 Invivoscribe, Inc.
11.12.1 Company Overview
11.12.2 Role of Invivoscribe, Inc. in the Global Next-Generation IVD Market
11.12.3 Recent Developments
11.12.3.1 Corporate Strategies
11.12.4 Analyst Perspective
11.13 PerkinElmer Inc.
11.13.1 Company Overview
11.13.2 Role of PerkinElmer Inc. in the Global Next-Generation IVD Market
11.13.3 Financials
11.13.4 Recent Developments
11.13.4.1 Corporate Strategies
11.13.4.2 Business Strategies
11.13.5 Analyst Perspective
11.14 QIAGEN N.V.
11.14.1 Company Overview
11.14.2 Role of QIAGEN N.V. in the Global Next-Generation IVD Market
11.14.3 Financials
11.14.4 Recent Developments
11.14.4.1 Corporate Strategies
11.14.4.2 Business Strategies
11.14.5 Analyst Perspective
11.15 Quest Diagnostics Incorporated
11.15.1 Company Overview
11.15.2 Role of Quest Diagnostics Incorporated in the Global Next-Generation IVD Market
11.15.3 Financials
11.15.4 Analyst Perspective
11.16 Sysmex Corporation
11.16.1 Company Overview
11.16.2 Role of Sysmex Corporation in the Global Next-Generation IVD Market
11.16.3 Financials
11.16.4 Recent Developments
11.16.4.1 Business Strategies
11.16.5 Analyst Perspective
11.17 Laboratory Corporation of America Holdings.
11.17.1 Company Overview
11.17.2 Role of Laboratory Corporation of America Holdings. in Global Next-Generation IVD Market
11.17.3 Financials
11.17.4 Recent Developments
11.17.4.1 Business Strategies
11.17.5 Analyst’s Perspective
11.18 Myriad Genetics, Inc.
11.18.1 Company Overview
11.18.2 Role of Myriad Genetics, Inc. in the Global Next-Generation IVD Market
11.18.3 Financials
11.18.4 Analyst Perspective
11.19 Siemens Healthineers AG
11.19.1 Company Overview
11.19.2 Role of Siemens Healthineers AG in the Global Next-Generation IVD Market
11.19.3 Financials
11.19.4 Recent Developments
11.19.4.1 Corporate Strategies
11.19.4.2 Business Strategies
11.19.5 Analyst Perspective
11.2 Tempus
11.20.1 Company Overview
11.20.2 Role of Tempus in the Global Next-Generation IVD Market
11.20.3 Recent Developments
11.20.3.1 Business Strategies
11.20.4 Analyst Perspective
11.21 Thermo Fisher Scientific Inc.
11.21.1 Company Overview
11.21.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation IVD Market
11.21.3 Financials
11.21.4 Recent Developments
11.21.4.1 Corporate Strategies
11.21.4.2 Business Strategies
11.21.5 Analyst Perspective
11.22 Emerging Companies
11.22.1 Geneseeq Technology Inc.
11.22.2 Genes2Me
11.22.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
11.22.4 Spindiag GmbH
1.1 Product Definition
1.1.1 Inclusion and Exclusion Criteria
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Next-Generation IVD Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 Introduction
2.1.1 Global Next-Generation IVD Market Outlook
2.1.1.1 POC-IVD
2.1.1.2 Global Diagnostic Expenditures
2.1.1.3 Pricing Patterns of Next-Generation IVD
2.1.2 Market Size and Growth Potential
2.1.2.1 Short-Term Impact (2020-2025)
2.1.2.2 Long-Term Impact (2026-2033)
2.1.3 Product Benchmarking by Next- Generation In-vitro Diagnostics Market, (by Type)
2.2 COVID-19 Impact on the Next-Generation IVD Market
2.2.1 Impact on Operations
2.2.2 COVID-19 Impact: Current Scenario of the Market
2.2.3 Pre-COVID Assessment
2.2.4 Post-COVID-19 Market Assessment
3 INDUSTRY ANALYSIS
3.1 Legal Requirements
3.1.1 Legal Requirements and Framework in the U.S.
3.1.2 Legal Requirements and Framework in Europe
3.1.3 Legal Requirements and Framework in Asia-Pacific
3.1.4 Legal Requirement and Framework in Latin America
4 MARKET DYNAMICS
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Technological Advancements in Next-Generation In-Vitro Diagnostics Transforming Healthcare System
4.3.2 Rising Demand of POC Testing Boosting Next-Generation IVD Market
4.3.3 Growing Incidence of Chronic and Acute Diseases Demanding for Early Treatment
4.3.4 Boost in the Next-Generation IVD Market during COVID-19 Pandemic
4.4 Market Challenges
4.4.1 Regulatory Hurdles Related to Next-Generation IVD Technologies
4.4.2 Poor Reimbursement Scenario
4.5 Market Opportunities
4.5.1 Rising Number of Next-Generation IVD Companies Involved in Business Expansion
4.5.2 Inclination of Emerging Companies toward Next-Generation IVD
5 COMPETITIVE LANDSCAPE
5.1 Overview
5.2 Corporate Strategies
5.2.1 Acquisitions
5.2.2 Synergistic Activities
5.3 Business Strategies
5.3.1 Product Launches and Approvals
5.3.2 Business Expansions, Fundings, and Other Activities
5.4 Market Share Analysis
5.4.1 Market Share Analysis (by Company)
5.5 Growth Share Analysis
5.5.1 Growth Share Analysis (by Product)
6 GLOBAL NEXT-GENERATION IVD MARKET (BY PRODUCT), ($BILLION), 2022-2033
6.1 Overview
6.2 Consumables
6.3 Instruments
6.4 Software
7 GLOBAL NEXT-GENERATION IVD MARKET (BY TYPE), ($BILLION), 2022-2033
7.1 Overview
7.2 Core Laboratory Diagnostics
7.2.1 Test Volume
7.2.2 Market Size and Forecast
7.2.2.1 Immunoassay
7.2.2.2 Hematology
7.2.2.3 Clinical Chemistry
7.2.2.4 Other Core Laboratory Diagnostics
7.3 POC Testing
7.3.1 Test Volume
7.3.2 Market Size and Forecast
7.4 Molecular Diagnostics
7.4.1 Test Volume
7.4.2 Market Size and Forecast
7.4.2.1 PCR
7.4.2.2 NGS
7.4.2.3 INAAT
7.4.2.4 Microarray
7.4.2.5 ISH
7.4.2.6 Immunohistochemistry
7.4.2.7 Other Molecular Diagnostics
8 GLOBAL NEXT-GENERATION IVD MARKETS (BY APPLICATION), $BILLION, 2022-2033
8.1 Overview
8.2 Diabetes
8.2.1 Type
8.2.2 Type
8.3 Infectious Diseases
8.3.1 Tuberculosis
8.3.2 Malaria
8.3.3 Hepatitis
8.3.4 Other Infectious Diseases
8.4 Oncology/Cancer
8.4.1 Solid Tumor
8.4.2 Hematological Malignancies
8.5 Cardiology
8.5.1 Cardiac Ischemia
8.5.2 Coronary Artery Diseases
8.6 Other Applications
9 GLOBAL NEXT-GENERATION IVD MARKET (BY END USER), ($BILLION), 2022-2033
9.1 Overview
9.1.1 Hospitals and Clinics
9.1.2 Diagnostic Laboratories
9.1.3 Academic and Research Institutions
9.1.4 Other End Users
10 GLOBAL NEXT-GENERATION IVD MARKET, BY REGION, $MILLION, 2022-2033
10.1 Overview
10.2 North America
10.2.1 Market Dynamics
10.2.2 Market Size and Forecast
10.2.2.1 North America Next-Generation IVD Market (by End User)
10.2.2.2 North America Next-Generation IVD Market (by Type)
10.2.2.2.1 North America Next-Generation Core Laboratory IVD Market, (by Type)
10.2.2.3 North America Next-Generation IVD Market (by Country)
10.2.2.3.1 U.S.
10.2.2.3.1.1 Market Size and Forecast
10.2.2.3.1.1.1 U.S. Next-Generation IVD Market (by End User)
10.2.2.3.1.1.2 U.S. Next-Generation IVD Market (by Type)
10.2.2.3.2 Canada
10.2.2.3.2.1 Market Size and Forecast
10.2.2.3.2.1.1 Canada Next-Generation IVD Market (by End User)
10.2.2.3.2.1.2 Canada Next-Generation IVD Market (by Type)
10.3 Europe
10.3.1 Market Dynamics
10.3.2 Market Size and Forecast
10.3.2.1 Europe Next-Generation IVD Market (by End User)
10.3.2.2 Europe Next-Generation IVD Market (by Type)
10.3.2.2.1 Europe Next-Generation Core Laboratory IVD Market, (by Type)
10.3.2.3 Europe Next-Generation IVD Market (by Country)
10.3.2.3.1 Germany
10.3.2.3.1.1 Market Size and Forecast
10.3.2.3.1.1.1 Germany Next-Generation IVD Market (by End User)
10.3.2.3.1.1.2 Germany Next-Generation IVD Market (by Type)
10.3.2.3.2 France
10.3.2.3.2.1 Market Size and Forecast
10.3.2.3.2.1.1 France Next-Generation IVD Market (by End User)
10.3.2.3.2.1.2 France Next-Generation IVD Market (by Type)
10.3.2.3.3 U.K.
10.3.2.3.3.1 Market Size and Forecast
10.3.2.3.3.1.1 U.K. Next-Generation IVD Market (by End User)
10.3.2.3.3.1.2 U.K. Next-Generation IVD Market (by Type)
10.3.2.3.4 Italy
10.3.2.3.4.1 Market Size and Forecast
10.3.2.3.4.1.1 Italy Next-Generation IVD Market (by End User)
10.3.2.3.4.1.2 Italy Next-Generation IVD Market (by Type)
10.3.2.3.5 Spain
10.3.2.3.5.1 Market Size and Forecast
10.3.2.3.5.1.1 Spain Next-Generation IVD Market (by End User)
10.3.2.3.5.1.2 Spain Next-Generation IVD Market (by Type)
10.3.2.3.6 Rest-of-Europe
10.3.2.3.6.1 Market Size and Forecast
10.3.2.3.6.1.1 Rest-of-Europe Next-Generation IVD Market (by End User)
10.3.2.3.6.1.2 Rest-of-Europe Next-Generation IVD Market (by Type)
10.4 Asia-Pacific
10.4.1 Market Dynamics
10.4.2 Market Size and Forecast
10.4.2.1 Asia-Pacific Next-Generation IVD Market (by End User)
10.4.2.2 Asia-Pacific Next-Generation IVD Market (by Type)
10.4.2.2.1 Asia-Pacific Next-Generation Core Laboratory IVD Market, (by Type)
10.4.2.3 Asia-Pacific Next-Generation IVD Market (by Country)
10.4.2.3.1 China
10.4.2.3.1.1 Market Size and Forecast
10.4.2.3.1.1.1 China Next-Generation IVD Market (by End User)
10.4.2.3.1.1.2 China Next-Generation IVD Market (by Type)
10.4.2.3.2 Japan
10.4.2.3.2.1 Market Size and Forecast
10.4.2.3.2.1.1 Japan Next-Generation IVD Market (by End User)
10.4.2.3.2.1.2 Japan Next-Generation IVD Market (by Type)
10.4.2.3.3 India
10.4.2.3.3.1 Market Size and Forecast
10.4.2.3.3.1.1 India Next-Generation IVD Market (by End User)
10.4.2.3.3.1.2 India Next-Generation IVD Market (by Type)
10.4.2.3.4 Australia
10.4.2.3.4.1 Market Size and Forecast
10.4.2.3.4.1.1 Australia Next-Generation IVD Market (by End User)
10.4.2.3.4.1.2 Australia Next-Generation IVD Market (by Type)
10.4.2.3.5 South Korea
10.4.2.3.5.1 Market Size and Forecast
10.4.2.3.5.1.1 South Korea Next-Generation IVD Market (by End User)
10.4.2.3.5.1.2 South Korea Next-Generation IVD Market (by Type)
10.4.2.3.6 Rest-of-Asia-Pacific
10.4.2.3.6.1 Market Size and Forecast
10.4.2.3.6.1.1 Rest-of-Asia-Pacific Next-Generation IVD Market (by End User)
10.4.2.3.6.1.2 Rest-of-Asia-Pacific Next-Generation IVD Market (by Type)
10.5 Latin America
10.5.1 Market Dynamics
10.5.2 Market Size and Forecast
10.5.2.1 Latin America Next-Generation IVD Market (by End User)
10.5.2.2 Latin America Next-Generation IVD Market (by Type)
10.5.2.2.1 Latin America Next-Generation Core Laboratory IVD Market, (by Type)
10.5.2.3 Latin America Next-Generation IVD Market (by Country)
10.5.2.3.1 Brazil
10.5.2.3.1.1 Market Size and Forecast
10.5.2.3.1.1.1 Brazil Next-Generation IVD Market (by End User)
10.5.2.3.1.1.2 Brazil Next-Generation IVD Market (by Type)
10.5.2.3.2 Mexico
10.5.2.3.2.1 Market Size and Forecast
10.5.2.3.2.1.1 Mexico Next-Generation IVD Market (by End User)
10.5.2.3.2.1.2 Mexico Next-Generation IVD Market (by Type)
10.5.2.3.3 Rest-of-Latin America
10.5.2.3.3.1 Market Size and Forecast
10.5.2.3.3.1.1 Rest-of-Latin America Next-Generation IVD Market (by End User)
10.5.2.3.3.1.2 Rest-of-Latin America Next-Generation IVD Market (by Type)
10.6 Middle East and Africa
10.6.1 Market Dynamics
10.6.2 Market Size and Forecast
10.6.2.1 Middle East and Africa Next-Generation IVD Market (by End User)
10.6.2.2 Middle East and Africa Next-Generation IVD Market (by Type)
10.6.2.2.1 Middle East and Africa Next-Generation Core Laboratory IVD Market, (by Type)
11 COMPANY PROFILES
11.1 Overview
11.2 Global Next-Generation IVD Market Ecosystem Active Players
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Role of Abbott Laboratories in the Global Next-Generation IVD Market
11.3.3 Financials
11.3.4 Recent Developments
11.3.4.1 Business Strategies
11.3.5 Analyst Perspective
11.4 Agilent Technologies, Inc.
11.4.1 Company Overview
11.4.2 Role of Agilent Technologies, Inc. in the Global Next-Generation IVD Market
11.4.3 Financials
11.4.4 Recent Developments
11.4.4.1 Corporate Strategies
11.4.4.2 Business Strategies
11.4.5 Analyst Perspective
11.5 Becton, Dickinson and Company
11.5.1 Company Overview
11.5.2 Role of Becton, Dickinson and Company in the Global Next-Generation IVD Market
11.5.3 Financials
11.5.4 Recent Developments
11.5.4.1 Corporate Strategies
11.5.4.2 Business Strategies
11.5.5 Analyst Perspective
11.6 bioMйrieux SA (BioFire Diagnostics)
11.6.1 Company Overview
11.6.2 Role of bioMйrieux SA (BioFire Diagnostics) in the Global Next-Generation IVD Market
11.6.3 Financials
11.6.4 Recent Developments
11.6.4.1 Corporate Strategies
11.6.4.2 Business Strategies
11.6.5 Analyst Perspective
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Company Overview
11.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation IVD Market
11.7.3 Financials
11.7.4 Recent Developments
11.7.4.1 Business Strategies
11.7.5 Analyst Perspective
11.8 Danaher Corporation
11.8.1 Company Overview
11.8.2 Role of Danaher Corporation in the Global Next-Generation IVD Market
11.8.3 Financials
11.8.4 Recent Developments
11.8.4.1 Corporate Strategies
11.8.4.2 Business Strategies
11.8.5 Analyst Perspective
11.9 F. Hoffmann-La Roche Ltd. (Roche Molecular Systems, Inc.)
11.9.1 Company Overview
11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation IVD Market
11.9.3 Financials
11.9.4 Recent Developments
11.9.4.1 Business Strategies
11.9.5 Analyst Perspective
11.1 Guardant Health
11.10.1 Company Overview
11.10.2 Role of Guardant Health in the Global Next-Generation IVD Market
11.10.3 Financials
11.10.4 Analyst Perspective
11.11 Illumina, Inc.
11.11.1 Company Overview
11.11.2 Role of Illumina, Inc. in the Global Next-Generation IVD Market
11.11.3 Financials
11.11.4 Recent Developments
11.11.4.1 Corporate Strategies
11.11.4.2 Business Strategies
11.11.5 Analyst Perspective
11.12 Invivoscribe, Inc.
11.12.1 Company Overview
11.12.2 Role of Invivoscribe, Inc. in the Global Next-Generation IVD Market
11.12.3 Recent Developments
11.12.3.1 Corporate Strategies
11.12.4 Analyst Perspective
11.13 PerkinElmer Inc.
11.13.1 Company Overview
11.13.2 Role of PerkinElmer Inc. in the Global Next-Generation IVD Market
11.13.3 Financials
11.13.4 Recent Developments
11.13.4.1 Corporate Strategies
11.13.4.2 Business Strategies
11.13.5 Analyst Perspective
11.14 QIAGEN N.V.
11.14.1 Company Overview
11.14.2 Role of QIAGEN N.V. in the Global Next-Generation IVD Market
11.14.3 Financials
11.14.4 Recent Developments
11.14.4.1 Corporate Strategies
11.14.4.2 Business Strategies
11.14.5 Analyst Perspective
11.15 Quest Diagnostics Incorporated
11.15.1 Company Overview
11.15.2 Role of Quest Diagnostics Incorporated in the Global Next-Generation IVD Market
11.15.3 Financials
11.15.4 Analyst Perspective
11.16 Sysmex Corporation
11.16.1 Company Overview
11.16.2 Role of Sysmex Corporation in the Global Next-Generation IVD Market
11.16.3 Financials
11.16.4 Recent Developments
11.16.4.1 Business Strategies
11.16.5 Analyst Perspective
11.17 Laboratory Corporation of America Holdings.
11.17.1 Company Overview
11.17.2 Role of Laboratory Corporation of America Holdings. in Global Next-Generation IVD Market
11.17.3 Financials
11.17.4 Recent Developments
11.17.4.1 Business Strategies
11.17.5 Analyst’s Perspective
11.18 Myriad Genetics, Inc.
11.18.1 Company Overview
11.18.2 Role of Myriad Genetics, Inc. in the Global Next-Generation IVD Market
11.18.3 Financials
11.18.4 Analyst Perspective
11.19 Siemens Healthineers AG
11.19.1 Company Overview
11.19.2 Role of Siemens Healthineers AG in the Global Next-Generation IVD Market
11.19.3 Financials
11.19.4 Recent Developments
11.19.4.1 Corporate Strategies
11.19.4.2 Business Strategies
11.19.5 Analyst Perspective
11.2 Tempus
11.20.1 Company Overview
11.20.2 Role of Tempus in the Global Next-Generation IVD Market
11.20.3 Recent Developments
11.20.3.1 Business Strategies
11.20.4 Analyst Perspective
11.21 Thermo Fisher Scientific Inc.
11.21.1 Company Overview
11.21.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation IVD Market
11.21.3 Financials
11.21.4 Recent Developments
11.21.4.1 Corporate Strategies
11.21.4.2 Business Strategies
11.21.5 Analyst Perspective
11.22 Emerging Companies
11.22.1 Geneseeq Technology Inc.
11.22.2 Genes2Me
11.22.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
11.22.4 Spindiag GmbH
LIST OF FIGURES
Figure 1: Facts about Global Next-Generation IVD Market
Figure 2: Equipment’s used for Next-Generation In-Vitro Diagnostics
Figure 3: Global Next-Generation IVD Market, $Billion, 2022 and 2033
Figure 4: Trend Analysis of Next-Generation In-vitro Diagnostics Ecosystem
Figure 5: Common Chronic Conditions for Population Above 65 years
Figure 6: Key Challenges in the Global Next-Generation IVD Market based on Primary Respondents
Figure 7: New In-Vitro Diagnostics Regulations (IVDR) and Medical Device Regulation (MDR)
Figure 8: Major Highlights Witnessed in the Next-Generation IVD Market During COVID-19 Impact
Figure 9: Role of POC Diagnostics in Next-Generation IVD Market During Pandemic
Figure 10: Leading and Emerging Companies in the Next-Generation IVD Ecosystem
Figure 11: Leading Companies in the Next-Generation IVD Ecosystem and Their Market Share (%)
Figure 12: Key Developments Undertaken by Companies in the Next-Generation IVD Market, July 2019-June 2023
Figure 13: Product Benchmarking of Next-Generation In-Vitro Diagnostics Ecosystem (by Test)
Figure 14: Global Next-Generation IVD Market (by Type), Share (%), 2022 and 2033
Figure 15: Global Next-Generation IVD Market (by Product), Share (%), 2022 and 2033
Figure 16: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033
Figure 17: Global Next-Generation IVD Market (by End User), Share (%), 2022 and 2033
Figure 18: Global Next-Generation In-Vitro Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 19: Europe Next-Generation IVD Market, Market Snapshot
Figure 20: Global Next-Generation IVD Market Segmentation
Figure 21: Global Next-Generation IVD Market: Research Methodology
Figure 22: Primary Research Methodology
Figure 23: Bottom-Up Approach (Segment-Wise Analysis)
Figure 24: Top-Down Approach (Segment-Wise Analysis)
Figure 25: Global Next-Generation IVD Market, $Billion, 2022-2033
Figure 26: Product Benchmarking of Next-Generation In-vitro Diagnostics Market (by Type)
Figure 27: In-Vitro Diagnostic Trends during the COVID-19 Pandemic
Figure 28: Timeline of IVDR 2017/746
Figure 29: Global Next-Generation IVD Market Dynamics
Figure 30: Factors Contributing to Growing Demand of POC Testing
Figure 31: Current Trend in In-Vitro Diagnostics: From Centralized Laboratory to Point-of-Care Testing
Figure 32: Annual Global Mortality by Chronic Illness in 1990, 2002, and 2020
Figure 33: Trend in COVID-19 Diagnostic Test Development and the Used Technology
Figure 34: Top Challenges in the IVDR Compliance
Figure 35: Key Area of Focus by Next-Generation IVD Companies
Figure 36: Share of Key Developments, July 2019-June 2023
Figure 37: Share of Acquisitions (by Company), July 2019-June 2023
Figure 38: Share of Synergistic Activities (by Company), July 2019-June 2023
Figure 39: Share of Product Launches and Approvals (by Company), July 2019-June 2023
Figure 40: Share of Business Expansions, Fundings, and Other Activities (by Company), July 2019-June 2023
Figure 41: Market Share Analysis of Global Next-Generation IVD Market (by Company), 2022
Figure 42: Growth Share Analysis for Global Next-Generation IVD Market (by Product), 2022
Figure 43: Global Next-Generation IVD Market (by Product)
Figure 44: Global Next-Generation IVD Market (by Product), $Billion, 2022 and 2033
Figure 45: Global Next-Generation IVD Market (Consumables), $Billion, 2022-2033
Figure 46: Global Next-Generation IVD Market (Instruments), $Billion, 2022-2033
Figure 47: Global Next-Generation IVD Market (Software), $Billion, 2022-2033
Figure 48: Global Next-Generation IVD Market (by Type)
Figure 49: Global Next-Generation IVD Market (by Type), $Billion, 2022 and 2033
Figure 50: Global Next-Generation IVD Market (Core Laboratory Diagnostics), Thousand Units, 2022-2033
Figure 51: Global Next-Generation IVD Market (Core Laboratory Diagnostics), $Billion, 2022-2033
Figure 52: Global Next-Generation IVD Market (Immunoassay), $Billion, 2022-2033
Figure 53: Global Next-Generation IVD Market (Hematology), $Billion, 2022-2033
Figure 54: Global Next-Generation IVD Market (Clinical Chemistry), $Billion, 2022-2033
Figure 55: Global Next-Generation IVD Market (Other Core Laboratory Diagnostics), $Billion, 2022-2033
Figure 56: Global Next-Generation IVD Market (POC Testing), Thousand Units, 2022-2033
Figure 57: Global Next-Generation IVD Market (POC Testing), $Billion, 2022-2033
Figure 58: Global Next-Generation IVD Market (Molecular Diagnostics), Thousand Units, 2022-2033
Figure 59: Global Next-Generation IVD Market (Molecular Diagnostics), $Billion, 2022-2033
Figure 60: Global Next-Generation IVD Market (PCR), $Billion, 2022-2033
Figure 61: Global Next-Generation IVD Market (NGS), $Billion, 2022-2033
Figure 62: Global Next-Generation IVD Market (INAAT), $Billion, 2022-2033
Figure 63: Global Next-Generation IVD Market (Microarray), $Billion, 2022-2033
Figure 64: Global Next-Generation IVD Market (ISH), $Billion, 2022-2033
Figure 65: Global Next-Generation IVD Market (Immunohistochemistry), $Billion, 2022-2033
Figure 66: Global Next-Generation IVD Market (Other Molecular Diagnostics), $Billion, 2022-2033
Figure 67: Global Next-Generation IVD Market (by Application)
Figure 68: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033
Figure 69: Global Next-Generation IVD Market (Diabetes), $Billion, 2022-2033
Figure 70: Global Next-Generation IVD Market (Type 1), $Billion, 2022-2033
Figure 71: Global Next-Generation IVD Market (Type 2), $Billion, 2022-2033
Figure 72: Global Next-Generation IVD Market (Infectious Diseases), $Billion, 2022-2033
Figure 73: Global Next-Generation IVD Market (Tuberculosis), $Billion, 2022-2033
Figure 74: Global Next-Generation IVD Market (Malaria), $Billion, 2022-2033
Figure 75: Global Next-Generation IVD Market (Hepatitis), $Billion, 2022-2033
Figure 76: Global Next-Generation IVD Market (Other Infectious Diseases), $Billion, 2022-2033
Figure 77: Global Next-Generation IVD Market (Oncology/Cancer), $Billion, 2022-2033
Figure 78: Global Next-Generation IVD Market (Solid Tumor), $Billion, 2022-2033
Figure 79: Global Next-Generation IVD Market (Hematological Malignancies), $Billion, 2022-2033
Figure 80: Global Next-Generation IVD Market (Cardiology), $Billion, 2022-2033
Figure 81: Global Next-Generation IVD Market (Cardiac Ischemia), $Billion, 2022-2033
Figure 82: Global Next-Generation IVD Market (Coronary Artery Diseases), $Billion, 2022-2033
Figure 83: Global Next-Generation IVD Market (Other Applications), $Billion, 2022-2033
Figure 84: Global Next-Generation IVD Market (by End User)
Figure 85: Global Next-Generation IVD Market (by End User), Share (%), 2022 and 2033
Figure 86: Global Next-Generation IVD Market (Hospitals and Clinics), $Billion, 2022-2033
Figure 87: Global Next-Generation IVD Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 88: Global Next-Generation IVD Market (Academic and Research Institutes), $Billion, 2022-2033
Figure 89: Global Next-Generation IVD Market (Other End Users), $Billion, 2022-2033
Figure 90: Global Next-Generation IVD Market (by Region), Share (%), 2022
Figure 91: Global Next-Generation IVD Market (by Region), $Billion, 2022-2033
Figure 92: North America Next-Generation IVD Market, $Billion, 2022-2033
Figure 93: North America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 94: North America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 95: North America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 96: North America Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 97: Factors Accelerating U.S. Next-Generation IVD Market
Figure 98: U.S. Next-Generation IVD Market, $Billion, 2022-2033
Figure 99: U.S. Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 100: U.S. Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 101: U.S. Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 102: Canada Next-Generation IVD Market, $Billion, 2022-2033
Figure 103: Canada Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 104: Canada Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 105: Canada Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 106: Europe Next-Generation IVD Market, $Billion, 2022-2033
Figure 107: Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 108: Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 109: Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 110: Europe Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 111: Germany Next-Generation IVD Market, $Billion, 2022-2033
Figure 112: Germany Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 113: Germany Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 114: Germany Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 115: France Next-Generation IVD Market, $Billion, 2022-2033
Figure 116: France Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 117: France Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 118: France Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 119: U.K. Next-Generation IVD Market, $Billion, 2022-2033
Figure 120: U.K. Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 121: U.K. Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 122: U.K. Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 123: Italy Next-Generation IVD Market, $Billion, 2022-2033
Figure 124: Italy Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 125: Italy Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 126: Italy Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 127: Spain Next-Generation IVD Market, $Billion, 2022-2033
Figure 128: Spain Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 129: Spain Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 130: Spain Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 131: Rest-of-Europe Next-Generation IVD Market, $Billion, 2022-2033
Figure 132: Rest-of-Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 133: Rest-of-Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 134: Rest-of-Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 135: Asia-Pacific Next-Generation IVD Market, $Billion, 2022-2033
Figure 136: Asia-Pacific Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 137: Asia-Pacific Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 138: Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 139: Asia-Pacific Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 140: China Next-Generation IVD Market, $Billion, 2022-2033
Figure 141: China Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 142: China Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 143: China Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 144: Japan Next-Generation IVD Market, $Billion, 2022-2033
Figure 145: Japan Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 146: Japan Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 147: Japan Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 148: India Next-Generation IVD Market, $Billion, 2022-2033
Figure 149: India Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 150: India Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 151: India Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 152: Australia Next-Generation IVD Market, $Billion, 2022-2033
Figure 153: Australia Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 154: Australia Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 155: Australia Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 156: South Korea Next-Generation IVD Market, $Billion, 2022-2033
Figure 157: South Korea Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 158: South Korea Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 159: South Korea Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 160: Rest-of-Asia-Pacific Next-Generation IVD Market, $Billion, 2022-2033
Figure 161: Rest-of-Asia-Pacific Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 162: Rest-of-Asia-Pacific Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 163: Rest-of-Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 164: Latin America Next-Generation IVD Market, $Billion, 2022-2033
Figure 165: Latin America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 166: Latin America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 167: Latin America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 168: Latin America Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 169: Brazil Next-Generation IVD Market, $Billion, 2022-2033
Figure 170: Brazil Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 171: Brazil Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 172: Brazil Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 173: Mexico Next-Generation IVD Market, $Billion, 2022-2033
Figure 174: Mexico Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 175: Mexico Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 176: Mexico Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 177: Rest-of-Latin America Next-Generation IVD Market, $Billion, 2022-2033
Figure 178: Rest-of-Latin America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 179: Rest-of-Latin America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 180: Rest-of-Latin America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 181: Middle East and Africa Next-Generation IVD Market, $Billion, 2022-2033
Figure 182: Middle East and Africa Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 183: Middle East and Africa Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 184: Middle East and Africa Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 185: Total Number of Companies Profiled
Figure 186: Abbott Laboratories: Product Portfolio
Figure 187: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 188: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 189: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 190: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 191: Agilent Technologies, Inc.: Product Portfolio
Figure 192: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 193: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 194: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 195: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 196: Becton, Dickinson and Company: Product Portfolio
Figure 197: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 198: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 199: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 200: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 201: bioMйrieux SA (BioFire Diagnostics): Product Portfolio
Figure 202: bioMйrieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
Figure 203: bioMйrieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
Figure 204: bioMйrieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
Figure 205: bioMйrieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
Figure 206: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 207: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 208: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 209: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 210: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 211: Danaher Corporation: Product Portfolio
Figure 212: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 213: Danaher Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 214: Danaher Corporation: Revenue (by Region), $Million, 2020-2022
Figure 215: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 216: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 217: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
Figure 218: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2020-2022
Figure 219: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2020-2022
Figure 220: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 221: Guardant Health: Product Portfolio
Figure 222: Guardant Health: Overall Financials, $Million, 2020-2022
Figure 223: Guardant Health: Revenue (by Segment), $Million, 2020-2022
Figure 224: Guardant Health: Revenue (by Region), $Million, 2020-2022
Figure 225: Guardant Health: R&D Expenditure, $Million, 2020-2022
Figure 226: Illumina, Inc.: Product Portfolio
Figure 227: Illumina, Inc.: Overall Financials, $Million, 2020-2022
Figure 228: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 229: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 230: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 231: Invivoscribe, Inc.: Product Portfolio
Figure 232: PerkinElmer Inc.: Product Portfolio
Figure 233: PerkinElmer Inc.: Overall Financials, $Million, 2020-2022
Figure 234: PerkinElmer Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 235: PerkinElmer Inc.: Revenue (by Region), $Million, 2020-2022
Figure 236: PerkinElmer Inc.: R&D Expenditure, $Million, 2020-2022
Figure 237: QIAGEN N.V.: Product Portfolio
Figure 238: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 239: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 240: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 241: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 242: Quest Diagnostics Incorporated: Product Portfolio
Figure 243: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
Figure 244: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2020-2022
Figure 245: Sysmex Corporation: Product Portfolio
Figure 246: Sysmex Corporation: Overall Financials, $Million, 2020-2022
Figure 247: Sysmex Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 248: Sysmex Corporation: Revenue (by Region), $Million, 2020-2022
Figure 249: Sysmex Corporation: R&D Expenditure, $Million, 2020-2022
Figure 250: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 251: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 252: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 253: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 254: Myriad Genetics, Inc.: Product Portfolio
Figure 255: Myriad Genetics, Inc.: Overall Financials, ($Million), 2020-2022
Figure 256: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 257: Myriad Genetics, Inc.: R&D Expenditure, ($Million), 2020-2022
Figure 258: Siemens Healthineers AG: Product Portfolio
Figure 259: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 260: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 261: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 262: Tempus: Product Portfolio
Figure 263: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 264: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 265: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 266: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 267: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
Figure 1: Facts about Global Next-Generation IVD Market
Figure 2: Equipment’s used for Next-Generation In-Vitro Diagnostics
Figure 3: Global Next-Generation IVD Market, $Billion, 2022 and 2033
Figure 4: Trend Analysis of Next-Generation In-vitro Diagnostics Ecosystem
Figure 5: Common Chronic Conditions for Population Above 65 years
Figure 6: Key Challenges in the Global Next-Generation IVD Market based on Primary Respondents
Figure 7: New In-Vitro Diagnostics Regulations (IVDR) and Medical Device Regulation (MDR)
Figure 8: Major Highlights Witnessed in the Next-Generation IVD Market During COVID-19 Impact
Figure 9: Role of POC Diagnostics in Next-Generation IVD Market During Pandemic
Figure 10: Leading and Emerging Companies in the Next-Generation IVD Ecosystem
Figure 11: Leading Companies in the Next-Generation IVD Ecosystem and Their Market Share (%)
Figure 12: Key Developments Undertaken by Companies in the Next-Generation IVD Market, July 2019-June 2023
Figure 13: Product Benchmarking of Next-Generation In-Vitro Diagnostics Ecosystem (by Test)
Figure 14: Global Next-Generation IVD Market (by Type), Share (%), 2022 and 2033
Figure 15: Global Next-Generation IVD Market (by Product), Share (%), 2022 and 2033
Figure 16: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033
Figure 17: Global Next-Generation IVD Market (by End User), Share (%), 2022 and 2033
Figure 18: Global Next-Generation In-Vitro Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 19: Europe Next-Generation IVD Market, Market Snapshot
Figure 20: Global Next-Generation IVD Market Segmentation
Figure 21: Global Next-Generation IVD Market: Research Methodology
Figure 22: Primary Research Methodology
Figure 23: Bottom-Up Approach (Segment-Wise Analysis)
Figure 24: Top-Down Approach (Segment-Wise Analysis)
Figure 25: Global Next-Generation IVD Market, $Billion, 2022-2033
Figure 26: Product Benchmarking of Next-Generation In-vitro Diagnostics Market (by Type)
Figure 27: In-Vitro Diagnostic Trends during the COVID-19 Pandemic
Figure 28: Timeline of IVDR 2017/746
Figure 29: Global Next-Generation IVD Market Dynamics
Figure 30: Factors Contributing to Growing Demand of POC Testing
Figure 31: Current Trend in In-Vitro Diagnostics: From Centralized Laboratory to Point-of-Care Testing
Figure 32: Annual Global Mortality by Chronic Illness in 1990, 2002, and 2020
Figure 33: Trend in COVID-19 Diagnostic Test Development and the Used Technology
Figure 34: Top Challenges in the IVDR Compliance
Figure 35: Key Area of Focus by Next-Generation IVD Companies
Figure 36: Share of Key Developments, July 2019-June 2023
Figure 37: Share of Acquisitions (by Company), July 2019-June 2023
Figure 38: Share of Synergistic Activities (by Company), July 2019-June 2023
Figure 39: Share of Product Launches and Approvals (by Company), July 2019-June 2023
Figure 40: Share of Business Expansions, Fundings, and Other Activities (by Company), July 2019-June 2023
Figure 41: Market Share Analysis of Global Next-Generation IVD Market (by Company), 2022
Figure 42: Growth Share Analysis for Global Next-Generation IVD Market (by Product), 2022
Figure 43: Global Next-Generation IVD Market (by Product)
Figure 44: Global Next-Generation IVD Market (by Product), $Billion, 2022 and 2033
Figure 45: Global Next-Generation IVD Market (Consumables), $Billion, 2022-2033
Figure 46: Global Next-Generation IVD Market (Instruments), $Billion, 2022-2033
Figure 47: Global Next-Generation IVD Market (Software), $Billion, 2022-2033
Figure 48: Global Next-Generation IVD Market (by Type)
Figure 49: Global Next-Generation IVD Market (by Type), $Billion, 2022 and 2033
Figure 50: Global Next-Generation IVD Market (Core Laboratory Diagnostics), Thousand Units, 2022-2033
Figure 51: Global Next-Generation IVD Market (Core Laboratory Diagnostics), $Billion, 2022-2033
Figure 52: Global Next-Generation IVD Market (Immunoassay), $Billion, 2022-2033
Figure 53: Global Next-Generation IVD Market (Hematology), $Billion, 2022-2033
Figure 54: Global Next-Generation IVD Market (Clinical Chemistry), $Billion, 2022-2033
Figure 55: Global Next-Generation IVD Market (Other Core Laboratory Diagnostics), $Billion, 2022-2033
Figure 56: Global Next-Generation IVD Market (POC Testing), Thousand Units, 2022-2033
Figure 57: Global Next-Generation IVD Market (POC Testing), $Billion, 2022-2033
Figure 58: Global Next-Generation IVD Market (Molecular Diagnostics), Thousand Units, 2022-2033
Figure 59: Global Next-Generation IVD Market (Molecular Diagnostics), $Billion, 2022-2033
Figure 60: Global Next-Generation IVD Market (PCR), $Billion, 2022-2033
Figure 61: Global Next-Generation IVD Market (NGS), $Billion, 2022-2033
Figure 62: Global Next-Generation IVD Market (INAAT), $Billion, 2022-2033
Figure 63: Global Next-Generation IVD Market (Microarray), $Billion, 2022-2033
Figure 64: Global Next-Generation IVD Market (ISH), $Billion, 2022-2033
Figure 65: Global Next-Generation IVD Market (Immunohistochemistry), $Billion, 2022-2033
Figure 66: Global Next-Generation IVD Market (Other Molecular Diagnostics), $Billion, 2022-2033
Figure 67: Global Next-Generation IVD Market (by Application)
Figure 68: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033
Figure 69: Global Next-Generation IVD Market (Diabetes), $Billion, 2022-2033
Figure 70: Global Next-Generation IVD Market (Type 1), $Billion, 2022-2033
Figure 71: Global Next-Generation IVD Market (Type 2), $Billion, 2022-2033
Figure 72: Global Next-Generation IVD Market (Infectious Diseases), $Billion, 2022-2033
Figure 73: Global Next-Generation IVD Market (Tuberculosis), $Billion, 2022-2033
Figure 74: Global Next-Generation IVD Market (Malaria), $Billion, 2022-2033
Figure 75: Global Next-Generation IVD Market (Hepatitis), $Billion, 2022-2033
Figure 76: Global Next-Generation IVD Market (Other Infectious Diseases), $Billion, 2022-2033
Figure 77: Global Next-Generation IVD Market (Oncology/Cancer), $Billion, 2022-2033
Figure 78: Global Next-Generation IVD Market (Solid Tumor), $Billion, 2022-2033
Figure 79: Global Next-Generation IVD Market (Hematological Malignancies), $Billion, 2022-2033
Figure 80: Global Next-Generation IVD Market (Cardiology), $Billion, 2022-2033
Figure 81: Global Next-Generation IVD Market (Cardiac Ischemia), $Billion, 2022-2033
Figure 82: Global Next-Generation IVD Market (Coronary Artery Diseases), $Billion, 2022-2033
Figure 83: Global Next-Generation IVD Market (Other Applications), $Billion, 2022-2033
Figure 84: Global Next-Generation IVD Market (by End User)
Figure 85: Global Next-Generation IVD Market (by End User), Share (%), 2022 and 2033
Figure 86: Global Next-Generation IVD Market (Hospitals and Clinics), $Billion, 2022-2033
Figure 87: Global Next-Generation IVD Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 88: Global Next-Generation IVD Market (Academic and Research Institutes), $Billion, 2022-2033
Figure 89: Global Next-Generation IVD Market (Other End Users), $Billion, 2022-2033
Figure 90: Global Next-Generation IVD Market (by Region), Share (%), 2022
Figure 91: Global Next-Generation IVD Market (by Region), $Billion, 2022-2033
Figure 92: North America Next-Generation IVD Market, $Billion, 2022-2033
Figure 93: North America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 94: North America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 95: North America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 96: North America Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 97: Factors Accelerating U.S. Next-Generation IVD Market
Figure 98: U.S. Next-Generation IVD Market, $Billion, 2022-2033
Figure 99: U.S. Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 100: U.S. Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 101: U.S. Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 102: Canada Next-Generation IVD Market, $Billion, 2022-2033
Figure 103: Canada Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 104: Canada Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 105: Canada Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 106: Europe Next-Generation IVD Market, $Billion, 2022-2033
Figure 107: Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 108: Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 109: Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 110: Europe Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 111: Germany Next-Generation IVD Market, $Billion, 2022-2033
Figure 112: Germany Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 113: Germany Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 114: Germany Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 115: France Next-Generation IVD Market, $Billion, 2022-2033
Figure 116: France Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 117: France Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 118: France Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 119: U.K. Next-Generation IVD Market, $Billion, 2022-2033
Figure 120: U.K. Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 121: U.K. Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 122: U.K. Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 123: Italy Next-Generation IVD Market, $Billion, 2022-2033
Figure 124: Italy Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 125: Italy Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 126: Italy Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 127: Spain Next-Generation IVD Market, $Billion, 2022-2033
Figure 128: Spain Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 129: Spain Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 130: Spain Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 131: Rest-of-Europe Next-Generation IVD Market, $Billion, 2022-2033
Figure 132: Rest-of-Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 133: Rest-of-Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 134: Rest-of-Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 135: Asia-Pacific Next-Generation IVD Market, $Billion, 2022-2033
Figure 136: Asia-Pacific Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 137: Asia-Pacific Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 138: Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 139: Asia-Pacific Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 140: China Next-Generation IVD Market, $Billion, 2022-2033
Figure 141: China Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 142: China Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 143: China Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 144: Japan Next-Generation IVD Market, $Billion, 2022-2033
Figure 145: Japan Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 146: Japan Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 147: Japan Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 148: India Next-Generation IVD Market, $Billion, 2022-2033
Figure 149: India Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 150: India Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 151: India Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 152: Australia Next-Generation IVD Market, $Billion, 2022-2033
Figure 153: Australia Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 154: Australia Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 155: Australia Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 156: South Korea Next-Generation IVD Market, $Billion, 2022-2033
Figure 157: South Korea Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 158: South Korea Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 159: South Korea Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 160: Rest-of-Asia-Pacific Next-Generation IVD Market, $Billion, 2022-2033
Figure 161: Rest-of-Asia-Pacific Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 162: Rest-of-Asia-Pacific Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 163: Rest-of-Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 164: Latin America Next-Generation IVD Market, $Billion, 2022-2033
Figure 165: Latin America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 166: Latin America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 167: Latin America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 168: Latin America Next-Generation IVD Market (by Country), $Billion, 2022-2033
Figure 169: Brazil Next-Generation IVD Market, $Billion, 2022-2033
Figure 170: Brazil Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 171: Brazil Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 172: Brazil Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 173: Mexico Next-Generation IVD Market, $Billion, 2022-2033
Figure 174: Mexico Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 175: Mexico Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 176: Mexico Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 177: Rest-of-Latin America Next-Generation IVD Market, $Billion, 2022-2033
Figure 178: Rest-of-Latin America Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 179: Rest-of-Latin America Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 180: Rest-of-Latin America Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 181: Middle East and Africa Next-Generation IVD Market, $Billion, 2022-2033
Figure 182: Middle East and Africa Next-Generation IVD Market (by End User), $Billion, 2022-2033
Figure 183: Middle East and Africa Next-Generation IVD Market (by Type), $Billion, 2022-2033
Figure 184: Middle East and Africa Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
Figure 185: Total Number of Companies Profiled
Figure 186: Abbott Laboratories: Product Portfolio
Figure 187: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 188: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 189: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 190: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 191: Agilent Technologies, Inc.: Product Portfolio
Figure 192: Agilent Technologies, Inc.: Overall Financials, $Million, 2020-2022
Figure 193: Agilent Technologies, Inc.: Net Revenue (by Segment), $Million, 2020-2022
Figure 194: Agilent Technologies, Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 195: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 196: Becton, Dickinson and Company: Product Portfolio
Figure 197: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 198: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 199: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 200: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 201: bioMйrieux SA (BioFire Diagnostics): Product Portfolio
Figure 202: bioMйrieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
Figure 203: bioMйrieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
Figure 204: bioMйrieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
Figure 205: bioMйrieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
Figure 206: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 207: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 208: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 209: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 210: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 211: Danaher Corporation: Product Portfolio
Figure 212: Danaher Corporation: Overall Financials, $Million, 2020-2022
Figure 213: Danaher Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 214: Danaher Corporation: Revenue (by Region), $Million, 2020-2022
Figure 215: Danaher Corporation: R&D Expenditure, $Million, 2020-2022
Figure 216: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 217: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
Figure 218: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2020-2022
Figure 219: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2020-2022
Figure 220: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
Figure 221: Guardant Health: Product Portfolio
Figure 222: Guardant Health: Overall Financials, $Million, 2020-2022
Figure 223: Guardant Health: Revenue (by Segment), $Million, 2020-2022
Figure 224: Guardant Health: Revenue (by Region), $Million, 2020-2022
Figure 225: Guardant Health: R&D Expenditure, $Million, 2020-2022
Figure 226: Illumina, Inc.: Product Portfolio
Figure 227: Illumina, Inc.: Overall Financials, $Million, 2020-2022
Figure 228: Illumina, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 229: Illumina, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 230: Illumina, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 231: Invivoscribe, Inc.: Product Portfolio
Figure 232: PerkinElmer Inc.: Product Portfolio
Figure 233: PerkinElmer Inc.: Overall Financials, $Million, 2020-2022
Figure 234: PerkinElmer Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 235: PerkinElmer Inc.: Revenue (by Region), $Million, 2020-2022
Figure 236: PerkinElmer Inc.: R&D Expenditure, $Million, 2020-2022
Figure 237: QIAGEN N.V.: Product Portfolio
Figure 238: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 239: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 240: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 241: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 242: Quest Diagnostics Incorporated: Product Portfolio
Figure 243: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
Figure 244: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2020-2022
Figure 245: Sysmex Corporation: Product Portfolio
Figure 246: Sysmex Corporation: Overall Financials, $Million, 2020-2022
Figure 247: Sysmex Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 248: Sysmex Corporation: Revenue (by Region), $Million, 2020-2022
Figure 249: Sysmex Corporation: R&D Expenditure, $Million, 2020-2022
Figure 250: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 251: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 252: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 253: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 254: Myriad Genetics, Inc.: Product Portfolio
Figure 255: Myriad Genetics, Inc.: Overall Financials, ($Million), 2020-2022
Figure 256: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 257: Myriad Genetics, Inc.: R&D Expenditure, ($Million), 2020-2022
Figure 258: Siemens Healthineers AG: Product Portfolio
Figure 259: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 260: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 261: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 262: Tempus: Product Portfolio
Figure 263: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 264: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 265: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 266: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 267: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
LIST OF TABLES
Table 1: Impact Analysis of Market Drivers, and Restraints on the Global Next-Generation IVD Market
Table 2: Impact of COVID-19 on Different Countries
Table 3: Likert Scale
Table 4: Impact Analysis of Market Drivers
Table 5: Impact Analysis of Market Restraints
Table 6: Impact Analysis of Market Opportunities
Table 7: Technology Offered by Next-Generation IVD Ecosystem
Table 8: Examples of Expansion Strategy by Global Next-Generation IVD Market Players
Table 9: Companies Offering Next-Generation-IVD Kits
Table 10: Companies Offering Next-Generation IVD Instruments
Table 11: Companies Offering Next-Generation IVD Software
Table 12: Companies Offering POC Test
Table 13: North America: Market Dynamics
Table 14: Europe: Market Dynamics
Table 15: Asia-Pacific: Market Dynamics
Table 16: Latin America: Market Dynamics
Table 17: Middle East and Africa: Market Dynamics
Table 18: Global Next-Generation IVD Market, Active Players
Table 1: Impact Analysis of Market Drivers, and Restraints on the Global Next-Generation IVD Market
Table 2: Impact of COVID-19 on Different Countries
Table 3: Likert Scale
Table 4: Impact Analysis of Market Drivers
Table 5: Impact Analysis of Market Restraints
Table 6: Impact Analysis of Market Opportunities
Table 7: Technology Offered by Next-Generation IVD Ecosystem
Table 8: Examples of Expansion Strategy by Global Next-Generation IVD Market Players
Table 9: Companies Offering Next-Generation-IVD Kits
Table 10: Companies Offering Next-Generation IVD Instruments
Table 11: Companies Offering Next-Generation IVD Software
Table 12: Companies Offering POC Test
Table 13: North America: Market Dynamics
Table 14: Europe: Market Dynamics
Table 15: Asia-Pacific: Market Dynamics
Table 16: Latin America: Market Dynamics
Table 17: Middle East and Africa: Market Dynamics
Table 18: Global Next-Generation IVD Market, Active Players
